First Treatment for Muscular Dystrophy in Sight
First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy
Skipping toward Personalized Molecular Medicine
Skipping toward Personalized Molecular Medicine
Dr. Eric Hoffman Op-Ed in the New England Journal of Medicine
Congress Appropriates Duchenne Muscular
Congress Appropriates Duchenne Muscular Dystrophy Translational Research Funding Through the Department of Defense.
Promising Dystrophy Drug Clears Early Test
Promising Dystrophy Drug Clears Early Test
http://www.nytimes.com/2007/12/27/health/27drug.html?_r=1&fta=y&oref=slogin
FED announces financial support for the first international workshop
FED announces financial support for the first international workshop on pre-clinical methods in mouse drug screening trials in the muscular dystrophies.
Senate proposes Duchenne muscular dystrophy translational research
Senate proposes Duchenne muscular dystrophy translational research earmarks within the Department of Defense.
Department of Defense approves $1.7 million of support
Department of Defense approves $1.7 million of support for clinical trial infrastructure to the Cooperative International Neuromuscular Research Group (CINRG).
The Program Project for Translational Researc
The Program Project for Translational Research in Muscular Dystrophy receives a $1.6 million boost from FY07 Department of Defense funding.
FED helps form the IDEW Group
FED helps form the IDEW Group (International Duchenne Exon-skipping Working Group) to push forward clinical trials in exon-skipping methods.
FED sponsors an international workshop
FED sponsors an international workshop on exon skipping approaches in Duchenne dystrophy.
FED funds large-scale production of multiple morpholinos
FED funds large-scale production of multiple morpholinos for systemic delivery trials.
